| Lecture venue | Biozentrum of the University of Basel
Basement, lecture hall as signposted
Spitalstrasse 41
4056 Basel
|
| Time | 18:00 (s.t.) |
| Interested in receiving invitations to the Basel IP Lecture? | Dr. Marita Wasner
e-mail: mail@niizumawasner.com
Niizuma Wasner GmbH | Lörracherstr. 122 | 4125 Riehen
Tel.: +41 61 811 8903 |
18 September 2024
Brian
Coggio
Fish
& Richardson, New York
Spotlight
on Life Sciences:
U.S. Growing Interest and Scrutiny in the Life Sciences Space – the FTC, PTO
and NIH
In September 2023,
the FTC together with the FDA announced the policy statement “Concerning Brand
Drug Manufacturers’ Improper Listing of Patents in the Orange Book”. Since
then, the FTC is investigating improper listing of patents in the Orange Book
and has taken action to ensure that certain patents are not listed and, if not
properly listed, removed. The notice also threatens legal action against
pharmaceutical companies for improper listing. Besides this, the USPTO has
issued a notice ensuring that all statements made to the USPTO in prosecuting a
patent are consistent with statements made to other government agencies such as
the FDA, or EMA. This will clearly increase the burden on patentees in
prosecuting pharmaceutical or any other patent when other agencies are
involved. Any failure could result in dire consequences to the patent owner and
the individual patent attorney involved. Moreover, the government has
highlighted the NIH’s authority via so-called March-In Rights to allow
competitors to manufacture patented products where the patentee prices are
deemed excessive. All three “attack’s” on the U.S. life sciences industry will
be discussed in the lecture. Finally, a short look will be taken to the effect
of the Inflation Reduction Act on patent strategy and pricing in the
pharmaceutical industry.
21 May 2024
Nicholas Mitrokostas
Partner at Allen & Overy, Boston
IP Considerations in view of
recent Life Sciences Developments using AI and Digital Health
In his lecture, Nick will focus
on recent developments relating to AI and patenting, including recent USPTO
directives, and the implications for obtaining and enforcing Life Sciences
patents that were developed using AI. Whether in a device or an app, the use of
AI in digital health has grown rapidly in the last several years, and the legal
issues surrounding the patentability and enforcement of intellectual property
protecting digital health innovation are evolving and in flux. This session
will cover recent U.S. court and USPTO developments concerning some of the key
legal considerations in digital health such as patent-eligible subject matter,
the enablement and written description requirements, and inventorship.
24 January 2024
Peter R. Thomsen
President of the epi
Current issues
addressed by the Institute of Professional Representatives before the EPO (epi)
The Institute of Professional
Representatives before the European Patent Office (epi) is the professional
body representing all European Patent Attorneys. The epi as an
organization deals primarily with the development and implications of patent law.
Through its Committees, the epi is at the forefront of patent law
developments and regularly serves public policy leaders by issuing legal
opinions and highly specialized advice. Besides this, the epi serves its
members by providing them with advice and training and keeping them informed
about latest developments.
In his function as president of the epi, Peter
will give some insights in the work of the epi with a particular focus on hot
topics the epi is currently working on, such as digitalization of the patent
granting procedure, oral proceedings, patent quality, fee increases and
reductions, and the future job profile of patent attorneys in the age of AI.
Moreover, he will briefly summarize the new procedure for the EQE.
